MannKind Corp (NASDAQ:MNKD)
| 1.93 Delayed Data As of Sep 17 |  +0.02 / +1.05%Today’s Change | 0.80 Today|||52-Week Range 2.48 | +49.22% Year-to-Date |
Latest MNKD News | Press Releases
| MannKind Corporation (MNKD) CEO Michael Castagna Presents at Cantor 2020 Global Virtual Healthcare Conference (Transcript) Sep 15 / Seeking Alpha - Paid Partner Content | MannKind Corporation's (MNKD) CEO Michael Castagna at H.C. Wainwright 22nd Annual Global Investment Conference (Transcript) Sep 14 / Seeking Alpha - Paid Partner Content |
| MannKind Corporation's (MNKD) CEO Michael Castagna at H.C. Wainwright 2second Annual Global Investment Conference (Transcript) Sep 14 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 1.91 |
| Today’s open | 1.91 |
| Day’s range | 1.85 - 2.15 |
| Volume | 5,097,836 |
| Average volume (3 months) | 3,172,537 |
| Market cap | $371.3M |
Data as of 3:59pm ET, 09/17/2020
Growth & Valuation
| Earnings growth (last year) | +56.02% |
| Earnings growth (this year) | +34.81% |
| Earnings growth (next 5 years) | +30.20% |
| Revenue growth (last year) | +126.28% |
| P/E ratio | NM |
| Price/Sales | 4.00 |
| Price/Book | -- |
Competitors
| ---- | ||
| BYSIBeyondspring Inc | +0.58 | +4.00% |
| OVIDOvid Therapeutics In... | +0.07 | +1.06% |
| AKBAAkebia Therapeutics ... | +0.28 | +10.49% |
Data as of 4:21pm ET, 09/17/2020
Financials
| Next reporting date | November 4, 2020 |
| EPS forecast (this quarter) | -$0.05 |
| Annual revenue (last year) | $63.0M |
| Annual profit (last year) | -$51.9M |
| Net profit margin | -82.34% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Westlake Village, California |
Forecasts
